News | Left Atrial Appendage (LAA) Occluders | December 18, 2019

First-Of-Its-Kind, No-Implant LAA Occluder Noted for Innovation at 2019 ICI Meeting

Append’s novel no-implant approach addresses common issues with AF treatment by closing the LAA with only a suture left at the closure site to prevent blood clot leakage and minimize device-related thromboembolism 

Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke risk in atrial fibrillation (AF) patients, announced that it has been selected from among hundreds of startups as a finalist for the ICI Innovation Award Competition. It uses a transcatheter lasso system so no implant is left behind and eliminates the possibility of embolization.

Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke risk in atrial fibrillation (AF) patients, announced that it has been selected from among hundreds of startups as a finalist for the ICI Innovation Award Competition. It uses a transcatheter lasso system so no implant is left behind and eliminates the possibility of embolization.


December 18, 2019 — Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke risk in atrial fibrillation (AF) patients, announced that it has been selected from among hundreds of startups as a finalist for the ICI Innovation Award Competition.

Append Medical will also present in the Digital Presentations: Complex Coronary and Valvular Interventions program during the meeting.

Current treatments for AF patients include anticoagulants and LAA closure devices, which are limited in effect due to high levels of non-compliance and bleeding risk (anticoagulants) and the risk of device leakage and device-related thromboembolism (closure devices).

Append’s novel no-implant approach addresses these issues by closing the LAA with only a suture left at the closure site to prevent blood clot leakage and minimize device-related thromboembolism. 

Originally conceived by Professor Leonid Sternik, MD, Director of the Department of Cardiac Surgery at Sheba Medical Center, the Append Medical “Appligator” device is designed to reduce stroke risk in AF patients by completely closing the LAA to prevent blood clot leakage. Its design is intended to minimize device-related thromboembolism risk by leaving only a suture – and no metal – at the closure site.

The LAA closure market is the second-fastest growing segment of the medical device market, estimated to reach $958 million by 2025, according to Energias Market Research.

The company operates as part of MEDX Xelerator in Israel. MEDX Xelerator’s partners include MEDX Ventures, Boston Scientific Inc., Intellectual Ventures and Sheba Medical Center.

For more information: wwwicimeeting.com.


Related Content

News | Left Atrial Appendage (LAA) Occluders

September 12, 2022 — Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval to ...

Home September 12, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

June 27, 2022 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias ...

Home June 28, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

April 12, 2022 – Patients who had leakage to the left atrial appendage due to incomplete device sealing after left ...

Home April 12, 2022
Home
News | Left Atrial Appendage (LAA) Occluders
February 28, 2022 – Boston Scientific Corporation has announced positive results from a new analysis assessing real ...
Home February 28, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

Home November 08, 2021
Home
Feature | Left Atrial Appendage (LAA) Occluders

September 27, 2021 — Compared with men undergoing left atrial appendage occlusion (LAAO), women have a significantly ...

Home September 27, 2021
Home
News | Left Atrial Appendage (LAA) Occluders

August 31, 2021 — Late-breaking data from a head-to-head clinical trial of the Amulet Left Atrial Appendage (LAA) ...

Home August 31, 2021
Home
News | Left Atrial Appendage (LAA) Occluders

August 16, 2021 — The U.S. Food and Drug Administration (FDA) approved Abbott's Amplatzer Amulet Left Atrial Appendage ...

Home August 16, 2021
Home
Feature | Left Atrial Appendage (LAA) Occluders

May 15, 2021 - Transcatheter left atrial appendage occlusion (LAAO) with a Boston Scientific Watchman device was ...

Home May 16, 2021
Home
News | Left Atrial Appendage (LAA) Occluders

May 15, 2021 — Patients with an elevated risk of stroke due to heart rhythm problems, or atrial fibrillation (AFib) ...

Home May 15, 2021
Home
Subscribe Now